This project will evaluate the effect of a single sub-anesthetic dose of ketamine on the time to first cocaine use and abstinence rates in 60 treatment-seeking cocaine-dependent individuals receiving mindfulness-based relapse prevention (MBRP) therapy, using a 5 week combined laboratory-inpatient and outpatient double-blind, randomized, controlled trial.
A single 40-minute intravenous infusion of ketamine (0.5 mg/kg) combined with a 5-week course of mindfulness-based relapse prevention (MBRP).
40-minute slow-drip infusion; combined with MBRP
A single 40-minute intravenous infusion of midazolam (0.025 mg/kg) combined with a 5-week course of mindfulness-based relapse prevention (MBRP).
40-minute slow-drip infusion; used as active control; combined with MBRP